• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Caring for Kids with HIV and TB

Hope for better treatments

Home > Stories

Caring for Kids with HIV and TB

Hope for better treatments

15 Feb 2017
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Sani sits in the doorway of her one-room house with her baby girl Mel in her arms. A pink sunset illuminates the Durban township of KwaMashu that unfolds below her clifftop house. She looks lovingly at Mel, then takes out a syringe and struggles to give the two-year-old a medicine that is over 40% alcohol. Mel swats away her mother’s hand, spits up the solution, cries.

This is a daily ritual for Sani Nojiyeza, 23, who like her daughter Mel is HIV positive. While Sani’s antiretroviral drugs are pretty easy to take, the only drugs available for Mel taste absolutely foul. Sani has tried mixing them with peanut butter or yoghurt but it doesn’t fully mask the taste.

Like many children living with HIV in Africa, Mel is also infected with tuberculosis (TB). This means Mel needs a large daily regimen of drugs combining HIV antiretrovirals and antibiotics for TB. “It’s heart-breaking to give so many treatments to a kid at the same time,” Sani says. She perseveres: if all goes well, Mel’s TB should be cured in six months. And the HIV treatment – if taken every day – will ensure that Mel has a long and fruitful life.

New infections have dropped by 70% since 2000, but 2000 children still die every week of HIV. Source: UNAIDS 2016

Luckily this scene is playing out less and less in Africa. Thanks to better prevention, fewer children are being born with HIV. New HIV infections in children have been dropped by 70% since 2000.

But children are still being born with HIV. Because almost no children are born with HIV in North America and Western Europe, children with HIV have been neglected by pharmaceutical innovation. The market for paediatric HIV drugs remains small. The foul-tasting antiretrovirals that Sani struggles to give every day are a direct result of this neglect.

Caring for children with HIV

King Edward VIII is a large, modern hospital in downtown Durban, about thirty minutes from Sani’s township. The HIV ward has a steady stream of paediatric patients. Most of the children come accompanied by their grandmothers. Busisiwe Dweku, 46, pictured above, collects a large plastic bag crammed full with bulky HIV medicines for her grandchild, Ngcobo.

“Over two million children have been orphaned by HIV/AIDS in South Africa”

Many of the mothers have passed away from AIDS-related causes, so the grandmothers take over care for their orphaned grandkids. Known as gogos – the Zulu word for “grandmother” – these women are the unsung heroes of the country’s AIDS crisis. Over two million children have been orphaned by HIV/AIDS in South Africa, leaving the gogos to keep families together.

They have a formidable task in taking care of the orphans that were born with HIV and often share the task with aunts and family friends. With such a large amount of medicines to give to a child, keeping track of the children’s many doses of medicine, and who gives them when, is very difficult.

Pictured below, Banele Dlamini, a gogo with her grandchildren in the HIV ward. Her daughter passed away from AIDS and she cares for her grandson Dudu, who is living with HIV.

Many of the children also struggle with TB infection, which adds yet more medicines to the burden. It also brings a further unique challenge for health workers to contend with: HIV and TB drugs can cancel each-other out.

“HIV and TB drugs can cancel each-other out”

Rifampicin is the antibiotic that forms the backbone of TB treatment. But the drug has the unintended effect of reducing the concentration and hence the effectiveness of lopinavir/ritonavir, one of the main World Health Organization (WHO) recommended treatments for children with HIV. To counteract this effect, the amount of ritonavir a child with both TB and HIV needs to take has to be increased, a procedure known as “super-boosting.”

But until recently health workers did not know for sure how to dose children with HIV and TB. Luckily, progress is being made.

A new hope for children with HIV and TB?

In a small trailer outside the HIV ward at the hospital, a clinical trial is being run by the Drugs for Neglected Diseases initiative (DNDi). Researchers are attempting to provide the evidence needed so that health workers know exactly how to treat kids co-infected with both HIV and TB. The children recruited into the trial are given the “super-boosted” treatment and are followed up closely by nurses over a period of time to see how the drugs work.

The site at King Edward’s is part of a larger study in five sites in South Africa that includes almost 100 kids. We were there:

In February 2017, DNDi presented the final results of this study, which provided the scientific proof needed so that health workers can give children the right dose. Based on interim results from the study, the WHO has recommended super-boosting in HIV/TB co-infected children.

Getting closer to “optimum” treatment

As the study wrapped up in July 2016, just ten minutes from King Edward’s, the International AIDS Conference is in full-swing in a packed convention hall. Thousands of researchers, activists, and celebrities from all over the world have descended on the town.  But Chirjeev Kindra, Medical Officer at the Hospital (pictured above), didn’t think about attending. “I have enough to do right here,” she muses.

Her ward has about 1,500 paediatric HIV patients. While she is proud that all of her kids have “undetectable” levels of HIV virus in their blood, a sure sign that the drugs are working, she admits the current treatments are a considerable challenge for the kids, the gogos and even for her team of health workers.

The problems are on many levels. Some of the drugs are so bitter the children refuse to take them. Others come in difficult to use and difficult to measure syrup formulations. Some also need to be kept cool, a problem for families all over Africa who don’t have refrigerators needed to store the treatments. There is a desperate need for new better formulations that are tailored to children’s needs:

DNDi’s ultimate goal for its paediatric HIV programme is to develop “4-in-1” fixed-dose combinations, which would combine the different WHO-recommended drugs into a pill that can be taken by infants and young chil­dren. DNDi is working with the Indian generic company Cipla to develop the drugs in pellet form, so that could be sprinkled on food.  Imagine the ideal scenario: no bitter tasting medicines. No need for refrigeration. No difficult to use syrups.

And thanks to what we now know about super-boosting, no problem treating both TB and HIV at the same time.

Hope for the future

Back at Sani’s house, the sun has set and her husband Brian joins her for dinner after a long day working in construction. He is HIV-negative, but tells us that when he found that his wife and child were HIV-positive, he stayed with them “out of love.”

We have all heard too many stories of families being torn apart by HIV, of husbands leaving their recently-diagnosed wives, but here was a man who was full of hope for his family’s future. Whether it’s Brian and his beloved family, or a devoted gogo and her grandchildren, caregivers just want the best hope – and the best treatment – for their kids.

Acknowledgements

DNDi’s HIV programme is supported by UBS Optimus Foundation, Switzerland; UNITAID, Switzerland; Médecins Sans Frontières, International; the Agence française de Développement, France; and a number of private donors.

Photo credit: Scholars & Gentlemen-DNDi

Children Paediatric HIV South Africa

Read, watch, share

Loading...
Centre of Excellence in India
News
14 Sep 2023

DNDi’s Centres of Excellence: Towards the sustainable elimination of visceral leishmaniasis in India

Delali Attip
Press releases
6 Sep 2023

Biotech leader Delali Attiogbe Attipoe joins DNDi as North America Director

Viewpoints
5 Sep 2023

Africa should bolster research into climate-sensitive diseases

Context
Prof. Sam Kariuki, DNDi Eastern Africa Director and Leonard Ithau, Rotary International District 9212 District Governor shaking hands
News
29 Aug 2023

DNDi and Rotary collaborate to prevent and treat diseases affecting neglected communities in Eastern Africa

Mother and child in a hospital
Viewpoints
24 Aug 2023

A drug development model for the diseases the world forgot

Africa Arguments
Statements
21 Aug 2023

DNDi urges G20 to operationalize equity in response to major global health challenges and priorities

Man looking into a microscope
Press releases
31 Jul 2023

Certara and DNDi partnering to fast-track data submissions and accelerate drug approvals for neglected patients

DNDi Prof. Fahal Interview 2023 Cover Image
Videos
25 Jul 2023

Prof. Fahal On The 20 Years of Innovating Together In Helping Mycetoma Patients

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo